Loading data...
Psilocybin-Research.com Searchable psilocybin and psilocin bibliometrics.

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

Research workflow

Search, filter, export, analyze, and monitor psilocybin and psilocin publications with source labels, publication status, citation links, alerts, API access, and full SQLite download.

Databases used

  • PubMed
  • Crossref
  • Europe PMC
  • OpenAlex
  • medRxiv
  • bioRxiv
  • PsyArXiv
  • ClinicalTrials.gov

Psilocybin and psilocin research index

Find psilocybin and psilocin papers, preprints, trials, and citations with clear source context.

Database 4,054 indexed records
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Database 4,054 indexed records
4,054 Total Publications 3,914 Psilocybin Records 569 Psilocin Records 569 Search Matches 826 Journals 66 Research Topics
Published 3,317 Peer-reviewed / formal records
Preprints 450 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 1,652 40.7% Active
OpenAlex 1,401 34.6% Active
ClinicalTrials.gov 287 7.1% Active
PubMed 278 6.9% Active
PsyArXiv 191 4.7% Active
bioRxiv 142 3.5% Active
Crossref 69 1.7% Active
Publication timeline 3,041 dated records
3,041 records since 2020
Annual records Cumulative line
Default publication index

Latest publications

569 records from the full SQLite publication database, sorted by newest first.

Result settings and export data
Updated Jul 5, 2026 01:22 UTC
Checking for newly indexed publications...
Page 3 of 29

Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms

Psilocybin is a naturally occurring psychedelic compound with potential antidepressant effects. Although it has long been used by humans, primarily for recreational purposes, the molecular mechanisms underlying its actions remain incompletely understood. Here, we examined the acute effects of psilocin, the active metabolite of psilocybin, on excitatory neuro...

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons

Abstract Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we ...

Presence of 4-Hydroxy-N-methyl-N-ethyltryptamine in Commercially Available Products.

Novel psychoactive substances (NPS) remain an ongoing challenge for public health, forensic laboratories, and regulatory agencies, especially when they are chemically related to controlled tryptamines but are marketed as legal alternatives. In the United States, the Federal Analogue Act (FAA) was intended to restrict such substances; however, regulatory loop...

The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior

BACKGROUND: The claustrum, a subcortical structure densely expressing 5-hydroxytryptamine 2 A (5-HT2A) receptors, has been implicated in sensory integration, emotional regulation, salience, and attention. Despite its hypothesized involvement in the effects of serotonergic psychedelics, the neurochemical impact of these substances on claustral neurotransmissi...

Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress

Anxiety disorders are chronic health conditions affecting the quality of life of millions of people. Psilocin, the active moiety of psilocybin, provides an anxiolytic effect; however, when orally administered as psilocybin, it only offers a moderate level of bioavailability and less predictable pharmacokinetics, potentially making effects after absorption va...

Optimization of Psilocybin Extraction from Psilocybe cubensis Mushrooms and Characterization of the Fungal Extract

Psilocybin is a molecule with significant potential for the treatment of mental disorders such as depression, anxiety, post-traumatic stress disorder, and substance abuse. In this study, it was explored the extraction of psilocybin from Psilocybe cubensis mushrooms using a factorial design approach, along with the physicochemical and phytochemical characteri...

The Effect of Magic Mushroom ( Psilocybe azurescens ) on Social Interaction, Anxiety- and Depressive-Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors

Psilocybin-containing mushrooms, commonly known as magic mushrooms, strongly affect mood, cognition, and behavior. Psilocybe azurescens is a species of psilocybin mushrooms that contains the main active compounds psilocybin and psilocin. Psilocybin mushrooms have been used since ancient times to improve the quality of life. However, their adverse effects hav...

Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex

Abstract Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder. Psilocybin is a psychedelic whose metabolite, psilocin, is a 5-HT2A receptor agonist. Nevertheless, the underlying mechanisms for the effects of psilocybin ...

Distinguishing 4- vs 5-Hydroxy-N,N-Dimethyltryptamine (Psilocin vs Bufotenine) Using Hydrogen-Deuterium Back-Exchange.

Distinguishing metabolite isomers often relies on comparing relative data, such as relative chromatographic retention times and ion mobility arrival time orders, or relative product ion abundances. These approaches necessitate the need for quality reference data and/or chemical standards. An ideal method for differentiating isomers would leverage one of the ...

Unknown journal 2025-12-29 Christopher MW, Prentice BM, Garrett TJ.

Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks

Background: Psilocybin has shown promise in neuropsychiatric disorders but presents a paradoxical relationship with seizures and epilepsy. Methods: A narrative review was conducted up to November 23, 2025. We conducted structured literature searches across PubMed/MEDLINE, Scopus, Web of Science. and Google Scholar using MeSH terms and keywords to identify st...

The genus Psilocybe in Italy

In the absence of specific studies on the Psilocybe genus in Italy, we provide information on the taxonomy, habitat, ecology, and distribution of the nine taxa currently recorded for Italy. A nomenclatural update of Psilocybe taxa reported in the Checklist of Italian Fungi (Basidiomycetes), published in 2005, is provided and seven scientific binomials are co...

From fungi to pharmacy: Applied technologies in psilocybin production and its therapeutic applications

Psilocybin, a naturally occurring tryptamine alkaloid found in over 200 species of fungi, has emerged as a focal point in the modern revival of psychedelic science. Once relegated to the margins of psychopharmacology due to its association with counterculture and strict legal restrictions, psilocybin is now undergoing a scientific renaissance. This transform...

Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats

Introduction:Psilocybin, a classical psychedelic, has shown to produce persistent antidepressant effects, including in patients with treatment-resistant depression. In clinical practice, it is common to coprescribe benzodiazepines (BZDs) alongside antidepressants. However, our preliminary study indicated that preadministration of lorazepam diminished the ant...

Unexpected Detection of Psilocybin in a 100 mg Tramadol Tablet: A Forensic Case Report

Background: Tramadol is a synthetic opioid analgesic prescribed for moderate pain. Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring psychoactive compound found in certain mushrooms, often referred to as "magic mushrooms" and is classified as a Schedule I substance. This case report aimed to present the unexpected detection of psil...

Acute Blockade of the Serotonin Transporter With Low Doses of Escitalopram Does Not Alter the Behavioural Responses to Acute Psilocybin

The psychedelic psilocybin has gained popularity in recent years as a therapy for treatment-resistant depression and has been reported to reduce symptoms of depression and anxiety. Psilocybin's active metabolite, psilocin, possesses a binding affinity for serotonin receptors as well as for the serotonin transporter (5-HTT). We recently reported that in contr...

Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.

Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent distressing thoughts and substantial anxiety, accompanied by repetitive behaviors or mental rituals. Individuals with OCD often have diminished quality of life, and functional impairment. The disorder cause high personal, societal and economic costs. Current availab...

Unmixing the Psychedelic Connectome: Brain Network Traits of Psilocybin

Psilocybin induces profound alterations in consciousness, yet prevailing neural models often describe a monolithic change in brain connectivity that may not fully capture the multifaceted nature of the psychedelic state. To test the hypothesis of a composite neural state, this study applied a robust, data-driven framework, Connectome Independent Component An...

Novel qNMR Methodto Quantify Psilocybin and Psilocinin Psychedelic Mushrooms

Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical investigation for the treatment of depression and other psychiatric conditions. However, the accurate quantification of these alkaloids in fungal matrices remains analytically challenging. Here, we report an optimized ...

Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms

High Resolution Image Download MS PowerPoint Slide Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical investigation for the treatment of depression and other psychiatric conditions. However, the accurate quantification of these alkaloids in fungal matrices remains anal...

Live source coverage

4,054 indexed records across 8 active sources.

3,317Published
450Preprints
287Clinical trials
  1. Europe PMC 1,652 records · 40.7%
  2. OpenAlex 1,401 records · 34.6%
  3. ClinicalTrials.gov 287 records · 7.1%
  4. PubMed 278 records · 6.9%
  5. PsyArXiv 191 records · 4.7%
  6. bioRxiv 142 records · 3.5%
  7. Crossref 69 records · 1.7%
  8. medRxiv 34 records · 0.8%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.